Early treatment discontinuation and switching in first-line metastatic breast cancer: the role of patient-reported symptom burden

Author： Walker Mark Masaquel Anthony Kerr Jiandong Lalla Deepa Abidoye Oyewale Houts Arthur Schwartzberg Lee

Publisher： Springer Publishing Company

ISSN： 0167-6806

Source： Breast Cancer Research and Treatment, Vol.144, Iss.3, 2014-04, pp. : 673-681

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Postmenopausal Metastatic Breast Cancer: A Review of First-Line Treatment Options

By Assersohn L. Johnston S.R.D.

American Journal of Cancer, Vol. 2, Iss. 2, 2003-01 ,pp. : 95-109

Adis International

Access to resources Recommend Favorite

First-Line Treatment of Metastatic Breast Cancer: Available Evidence and Current Recommendations

By Puglisi Fabio

American Journal of Cancer, Vol. 5, Iss. 2, 2006-01 ,pp. : 99-110

Adis International

Access to resources Recommend Favorite

Gemcitabine: In Combination with Paclitaxel in the First-Line Treatment of Metastatic Breast Cancer

By Moen Marit D. Wellington Keri

American Journal of Cancer, Vol. 4, Iss. 5, 2005-01 ,pp. : 327-333

Adis International

Access to resources Recommend Favorite

Influence of Droloxifene on Metastatic Breast Cancer as First-Line Endocrine Treatment

By Haarstad Helge Lønning Per E. Gundersen Stein Wist Erik Raabe Nils Kvinnsland Stener

Acta Oncologica, Vol. 37, Iss. 4, 1998-10 ,pp. : 365-368

Informa Healthcare

Access to resources Recommend Favorite

Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer

By Riemsma Rob

Breast Cancer Research and Treatment, Vol. 123, Iss. 1, 2010-08 ,pp. : 9-24

Springer Publishing Company

Access to resources Recommend Favorite